Abnova Taiwan Corp (4133) - Net Assets
Based on the latest financial reports, Abnova Taiwan Corp (4133) has net assets worth NT$1.27 Billion TWD (≈ $40.11 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$1.35 Billion ≈ $42.62 Million USD) and total liabilities (NT$79.68 Million ≈ $2.51 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how strategically is Abnova Taiwan Corp's equity deployed to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$1.27 Billion |
| % of Total Assets | 94.11% |
| Annual Growth Rate | 3.13% |
| 5-Year Change | 3.69% |
| 10-Year Change | 6.83% |
| Growth Volatility | 14.96 |
Abnova Taiwan Corp - Net Assets Trend (2008–2025)
This chart illustrates how Abnova Taiwan Corp's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see 4133 market cap.
Annual Net Assets for Abnova Taiwan Corp (2008–2025)
The table below shows the annual net assets of Abnova Taiwan Corp from 2008 to 2025. Also explore net asset growth rate of Abnova Taiwan Corp to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | NT$1.26 Billion ≈ $39.59 Million |
-4.04% |
| 2024-12-31 | NT$1.31 Billion ≈ $41.25 Million |
+1.79% |
| 2023-12-31 | NT$1.29 Billion ≈ $40.53 Million |
-0.44% |
| 2022-12-31 | NT$1.29 Billion ≈ $40.70 Million |
+6.62% |
| 2021-12-31 | NT$1.21 Billion ≈ $38.18 Million |
+0.05% |
| 2020-12-31 | NT$1.21 Billion ≈ $38.16 Million |
+1.57% |
| 2019-12-31 | NT$1.19 Billion ≈ $37.57 Million |
-2.84% |
| 2018-12-31 | NT$1.23 Billion ≈ $38.66 Million |
+0.20% |
| 2017-12-31 | NT$1.22 Billion ≈ $38.59 Million |
+4.12% |
| 2016-12-31 | NT$1.18 Billion ≈ $37.06 Million |
+0.82% |
| 2015-12-31 | NT$1.17 Billion ≈ $36.76 Million |
-5.13% |
| 2014-12-31 | NT$1.23 Billion ≈ $38.74 Million |
0.00% |
| 2013-12-31 | NT$1.23 Billion ≈ $38.74 Million |
+0.07% |
| 2012-12-31 | NT$1.23 Billion ≈ $38.72 Million |
-3.28% |
| 2011-12-31 | NT$1.27 Billion ≈ $40.03 Million |
+0.06% |
| 2010-12-31 | NT$1.27 Billion ≈ $40.01 Million |
+4.94% |
| 2009-12-31 | NT$1.21 Billion ≈ $38.13 Million |
+62.59% |
| 2008-12-31 | NT$744.31 Million ≈ $23.45 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Abnova Taiwan Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 6484300000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | NT$64.84 Million | 5.16% |
| Common Stock | NT$605.54 Million | 48.19% |
| Other Comprehensive Income | NT$111.59 Million | 8.88% |
| Other Components | NT$474.53 Million | 37.77% |
| Total Equity | NT$1.26 Billion | 100.00% |
Abnova Taiwan Corp Competitors by Market Cap
The table below lists competitors of Abnova Taiwan Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ACELRX PHARMACEUT. DL-01
F:R5XA
|
$38.92 Million |
|
IFirma SA
WAR:IFI
|
$38.93 Million |
|
Oricom Inc
KQ:010470
|
$38.93 Million |
|
Eightco Holdings Inc.
NASDAQ:OCTO
|
$38.94 Million |
|
Sealink International Bhd
KLSE:5145
|
$38.92 Million |
|
IRIS Corporation Bhd
KLSE:0010
|
$38.91 Million |
|
KRONA PUBLIC REAL ESTATE
F:927
|
$38.89 Million |
|
Dividend Select 15 Corp
TO:DS
|
$38.86 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Abnova Taiwan Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,309,400,000 to 1,256,495,000, a change of -52,905,000 (-4.0%).
- Net loss of 1,141,000 reduced equity.
- Dividend payments of 54,498,000 reduced retained earnings.
- Other comprehensive income increased equity by 4,111,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$-1.14 Million | -0.09% |
| Dividends Paid | NT$54.50 Million | -4.34% |
| Other Comprehensive Income | NT$4.11 Million | +0.33% |
| Other Changes | NT$-1.38 Million | -0.11% |
| Total Change | NT$- | -4.04% |
Book Value vs Market Value Analysis
This analysis compares Abnova Taiwan Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.98x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2009-12-31 | NT$21.37 | NT$20.40 | x |
| 2010-12-31 | NT$20.43 | NT$20.40 | x |
| 2011-12-31 | NT$20.43 | NT$20.40 | x |
| 2012-12-31 | NT$19.74 | NT$20.40 | x |
| 2013-12-31 | NT$19.77 | NT$20.40 | x |
| 2014-12-31 | NT$19.77 | NT$20.40 | x |
| 2015-12-31 | NT$19.06 | NT$20.40 | x |
| 2016-12-31 | NT$19.97 | NT$20.40 | x |
| 2017-12-31 | NT$20.19 | NT$20.40 | x |
| 2018-12-31 | NT$20.24 | NT$20.40 | x |
| 2019-12-31 | NT$19.69 | NT$20.40 | x |
| 2020-12-31 | NT$19.99 | NT$20.40 | x |
| 2021-12-31 | NT$20.00 | NT$20.40 | x |
| 2022-12-31 | NT$21.30 | NT$20.40 | x |
| 2023-12-31 | NT$21.22 | NT$20.40 | x |
| 2024-12-31 | NT$21.58 | NT$20.40 | x |
| 2025-12-31 | NT$20.75 | NT$20.40 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Abnova Taiwan Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -0.09%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -0.32%
- • Asset Turnover: 0.26x
- • Equity Multiplier: 1.06x
- Recent ROE (-0.09%) is below the historical average (4.92%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2008 | 5.26% | 14.48% | 0.32x | 1.15x | NT$-35.29 Million |
| 2009 | 8.23% | 24.71% | 0.31x | 1.08x | NT$-21.46 Million |
| 2010 | 11.74% | 31.37% | 0.36x | 1.05x | NT$22.06 Million |
| 2011 | 9.43% | 25.36% | 0.35x | 1.07x | NT$-7.20 Million |
| 2012 | 6.25% | 16.57% | 0.36x | 1.05x | NT$-46.06 Million |
| 2013 | 5.93% | 15.72% | 0.36x | 1.05x | NT$-50.08 Million |
| 2014 | 5.34% | 14.98% | 0.33x | 1.06x | NT$-57.33 Million |
| 2015 | 3.85% | 9.95% | 0.36x | 1.07x | NT$-71.75 Million |
| 2016 | 4.55% | 12.17% | 0.35x | 1.06x | NT$-64.08 Million |
| 2017 | 4.81% | 12.41% | 0.36x | 1.06x | NT$-63.51 Million |
| 2018 | 3.76% | 10.83% | 0.33x | 1.06x | NT$-76.61 Million |
| 2019 | 0.27% | 0.79% | 0.33x | 1.06x | NT$-115.98 Million |
| 2020 | 3.02% | 8.00% | 0.35x | 1.07x | NT$-84.58 Million |
| 2021 | 2.34% | 6.28% | 0.35x | 1.06x | NT$-92.81 Million |
| 2022 | 5.79% | 18.18% | 0.30x | 1.06x | NT$-54.36 Million |
| 2023 | 3.40% | 11.43% | 0.28x | 1.05x | NT$-84.95 Million |
| 2024 | 4.70% | 17.34% | 0.25x | 1.07x | NT$-69.33 Million |
| 2025 | -0.09% | -0.32% | 0.26x | 1.06x | NT$-126.79 Million |
Industry Comparison
This section compares Abnova Taiwan Corp's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,324,002,500
- Average return on equity (ROE) among peers: 2.53%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Abnova Taiwan Corp (4133) | NT$1.27 Billion | 5.26% | 0.06x | $38.92 Million |
| Apex Biotechnology Corp (1733) | $1.80 Billion | 6.44% | 0.28x | $95.57 Million |
| Sinphar Pharmaceutical Co Ltd (1734) | $3.78 Billion | 0.44% | 0.64x | $188.76 Million |
| Panion & BF Biotech Inc (1760) | $1.35 Billion | 11.79% | 0.36x | $146.95 Million |
| Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) | $1.68 Billion | 10.48% | 0.80x | $81.91 Million |
| SYN-Tech Chem & Pharm Co Ltd (1777) | $996.24 Million | 6.00% | 0.56x | $103.82 Million |
| Level Biotechnology (3118) | $542.40 Million | 10.78% | 0.50x | $32.36 Million |
| GenMont Biotech Inc (3164) | $294.16 Million | -11.68% | 0.05x | $42.81 Million |
| Medigen Biotechnology (3176) | $650.39 Million | 0.00% | 0.08x | $175.12 Million |
| Sagittarius Life Science (3205) | $588.38 Million | -12.60% | 0.26x | $99.27 Million |
| Genovate Biotechnology Co Ltd (4130) | $1.56 Billion | 3.70% | 0.11x | $115.03 Million |
About Abnova Taiwan Corp
Abnova (Taiwan) Corporation engages in the research, development, manufacturing, and sales of monoclonal and multiclonal antibodies, proteins, medical diagnostic instruments, and testing reagents. The company's products portfolio includes SARS-CoV/CoV-2, DNA, RNA, proteins/peptides, lysates/slides, Ab pairs/kits, Ab arrays, polyclinic antibody, beads/dyes, in situ hybridization products, systems,… Read more